Pro Salus Sp. z o.o.,sp. k.

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease2 trials
• Chronic kidney disease1 trial
• High blood pressure1 trial
• Multiple sclerosis1 trial
• Schizophrenia1 trial
• Type 2 diabetes1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Recruiting4 trials
• Completed1 trial

Lead sponsor

• Boehringer Ingelheim2 trials
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
• Zenas BioPharma (USA), LLC1 trial

Running trials

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• High blood pressure1 recruiting
• Multiple sclerosis1 recruiting
• Schizophrenia1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source